Full-Time

Analytical Development Manager

Analytics

Deadline 9/18/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Mumbai, Maharashtra, India

In Person

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Data Governance
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Strong knowledge of pharmaceutical analytical development for synthetic compounds and drug products.
  • Extensive experience in analytical method development, validation, transfer, verification, and lifecycle management.
  • Experience supporting stability studies and development programs across clinical and commercial phases.
  • Strong understanding of analytical techniques including chromatography, dissolution, spectroscopy, solid state characterization, and impurity profiling techniques.
  • Strong understanding of Chemistry, Manufacturing, and Controls development requirements.
  • Deep knowledge of International Council for Harmonisation guidelines, pharmacopoeia requirements, and current global regulatory expectations.
  • Experience supporting New Drug Application, Marketing Authorisation Application, and Abbreviated New Drug Application submissions and health authority interactions.
  • Knowledge of quality systems, Good Manufacturing Practice, data integrity, and laboratory compliance requirements.
  • Project management and resource planning experience.
  • Risk assessment and problem-solving skills.
  • Cross-functional stakeholder management experience.
  • Strategic planning and execution skills.
  • Proven leadership experience managing scientific teams.
  • Strong coaching, mentoring, and talent development capabilities.
  • Ability to lead through organizational change and ambiguity.
  • High level of emotional intelligence and influencing skills.
  • Strong collaboration and stakeholder management capabilities.
  • Excellent verbal, written, and presentation skills.
  • Ability to drive accountability, engagement, and performance.
  • Strategic mindset with a strong execution focus.
  • Demonstrated ability to build inclusive, diverse, and high-performing teams.
  • Bachelor's or Master's degree in Analytical Chemistry, Pharmaceutical Sciences, Chemistry, Pharmacy, or a related discipline with significant industry experience.
  • Ph.D. in Analytical Chemistry, Pharmaceutical Sciences, Chemistry, or a related scientific discipline.
  • Minimum 12 to 15+ years of pharmaceutical analytical development experience.
  • Minimum 5 years of leadership experience managing scientific teams.
  • Experience supporting global pharmaceutical development programs.
  • Experience with regulatory inspections and health authority interactions.
  • Experience leading cross-functional development projects in a global environment.
Responsibilities
  • Lead analytical development activities for synthetic drug products and new modality programs from development through commercialization.
  • Provide scientific oversight for analytical method development, validation, transfer, method robustness assessments, and technical troubleshooting activities.
  • Participate in stability strategy development and support stability studies across development phases.
  • Ensure generation of high-quality analytical data and technical documentation supporting global regulatory submissions.
  • Review and approve analytical protocols, reports, specifications, validation documents, and technical assessments.
  • Provide scientific leadership during investigations, root cause analysis, risk assessments, and implementation of corrective actions.
  • Drive implementation of innovative analytical technologies, digital tools, and industry best practices.
  • Support health authority inspections and responses to regulatory agency queries.
  • Lead planning, prioritization, and execution of project deliverables within internal teams across multiple development programs.
  • Collaborate with Pharmaceutical Development, Regulatory Affairs, Quality, Manufacturing laboratories, and external partners to ensure project success.
  • Monitor project timelines, resource utilization, risks, and mitigation plans to ensure on-time delivery.
  • Support strategic portfolio planning and capacity management activities.
  • Drive continuous improvement initiatives that enhance efficiency, quality, and compliance.
  • Lead, coach, and develop a team of scientists.
  • Establish a high-performance culture focused on accountability, ownership, scientific excellence, and collaboration.
  • Conduct talent management activities such as performance and development planning, succession planning, and career development activities.
  • Identify capability gaps and implement development plans to build future organizational capabilities.
  • Foster an inclusive work environment that promotes innovation, engagement, and employee well-being.
  • Ensure effective onboarding, mentoring, and technical training of team members.
  • Ensure compliance with Good Manufacturing Practice, data integrity, safety, and company quality requirements.
  • Maintain inspection readiness and participate in internal and regulatory audits, leading discussions for the given scope of work.
  • Ensure adherence to environment, health, and safety policies and procedures.
  • Manage departmental resources and laboratory operational excellence initiatives.
  • Promote continuous improvement through digital and process excellence principles.
Desired Qualifications
  • Mass spectrometry expertise.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.